Date of this Version
11-28-2023
Document Type
DNP Project
Abstract
Background: Inflammatory bowel disease (IBD) patients experience more pain and discomfort during colonoscopy due to the nature of the disease. They are often young, highly anxious before the procedure, and have undergone many previous colonoscopies, which are known risk factors for intolerance to the procedure. Currently, the sedative drugs used with these procedures are primarily propofol and midazolam. Midazolam possesses a prolonged half-life, necessitating a lengthier recovery period from anesthesia for patients. In this patient population, the utilization of a new drug called remimazolam as an alternative can lead to improved outcomes.
Methods: A thorough search of research was performed utilizing PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Google Scholar to distinguish research studies published within the past ten years that have assessed the efficacy of remimazolam to midazolam and/or another anesthetic agent in similar populations. Using the literature review, an educational module was presented to educate providers on the use of remimazolam.
Results: The educational module resulted in a boost in providers' knowledge and attitudes concerning remimazolam, leading to its increased utilization for IBD patients undergoing endoscopic procedures.
Recommended Citation
Perez, Alexis; Valdes, Jorge; and Gil, Jillian, "Advantages of Intravenous Administration of Remimazolam Over Midazolam in Inflammatory Bowel Disease Patients Undergoing Endoscopic Procedures: An Educational Module" (2023). Nicole Wertheim College of Nursing Student Projects. 220.
https://digitalcommons.fiu.edu/cnhs-studentprojects/220